Table 3.

Linear and Logistic Regression Analysis of Blood Pressure Outcomes Associated With Urinary Phthalate Metabolites

Blood Pressure Outcome (n=1329)Z-Score Increment,* Systolic Blood PressureZ-Score Increment,* Diastolic Blood PressureOdds Ratio, Blood Pressure ≥90th Percentile
LMW metabolites+0.02 (−0.05, +0.10)+0.04 (−0.16, +0.24)1.12 (0.79, 1.59)
HMW metabolites+0.12 (+0.03, +0.21)+0.06 (−0.03, +0.16)1.30 (0.78, 2.17)
DEHP metabolites+0.10 (+0.03, +0.18)+0.09 (+0.04, +0.17)1.31 (0.90, 1.91)
DIDP metabolites+0.11 (+0.04, +0.17)+0.03 (−0.04, +0.10)0.99 (0.66, 1.48)
DINP metabolites+0.11 (+0.03, +0.19)+0.02 (−0.09, +0.13)1.19 (0.72, 1.98)
  • BMI indicates body mass index; DEHP indicates di-2-ethylhexylphthalate; DIDP, di-isodecyl phthalate; DINP, di-isononyl phthalate; HMW, low-molecular weight; and LMW, low-molecular weight.

  • * Increases are per log unit in urinary LMW/HMW/DEHP/DINP/DIDP metabolite concentration. See Methods for calculation. Models control for sex, caloric intake, physical activity, poverty–income ratio, serum cotinine, urinary creatinine, BMI category, race/ethnicity, and age categories. Results using weighted modeling are presented.

  • P<0.05.

  • P<0.01.